Lauren C. Frey, MD

At least 30% of patients with epilepsy have seizures that are incompletely controlled by medical therapy; thus, nonpharmacological options are important for comprehensive care.

Advances in the diagnosis and management of SMA include molecular genetic testing and the FDA approval of a disease-modifying therapy.